FDA Update: New Tool Shows Chemical Contaminant Levels in Food for Greater Transparency

by David Randall | Mar 27, 2025 | FDA, Trending News

For Immediate Release: March 20, 2025 Today, under the leadership of U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr., the U.S. Food and Drug Administration unveiled the Chemical Contaminants Transparency Tool (CCT Tool), an online...

FDA Update: New Kidney Drug Approved, Medical Device Alert Issued, and Colonoscopy Cleaner AuthorizedFDA Roundup: March 21, 2025

by David Randall | Mar 27, 2025 | FDA, Trending News

For Immediate Release: March 21, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G)...

FDA News Update: First Nicotine Pouches Receive Marketing Authorization Under Premarket Review

by David Randall | Feb 12, 2025 | FDA, Trending News

For Immediate Release: January 16, 2025 Today, the U.S. Food and Drug Administration authorized the marketing of 20 ZYN nicotine pouch products through the premarket tobacco product application (PMTA) pathway following an extensive scientific review. This is the first...

FDA News Update: Food Safety, Medical Advances, and New Regulatory Actions

by David Randall | Feb 12, 2025 | FDA, Trending News

For Immediate Release: January 17, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA announced the release of a new prevention strategy aimed at combating the contamination of fresh and...

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

by David Randall | Feb 12, 2025 | FDA, Trending News

For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting...